Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Esperion TherapeuticsCollegium PharmaceuticalProvention BioAnaptysBioMerus
SymbolNASDAQ:ESPRNASDAQ:COLLNASDAQ:PRVBNASDAQ:ANABNASDAQ:MRUS
Price Information
Current Price$27.48$22.86$7.82$22.08$22.02
52 Week RangeHoldHoldBuyHoldBuy
MarketRank™
Overall Score1.21.41.61.51.8
Analysis Score3.21.14.43.13.4
Community Score2.82.52.72.82.5
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.81.72.5
Earnings & Valuation Score0.03.10.00.00.6
Analyst Ratings
Consensus RecommendationHoldHoldBuyHoldBuy
Consensus Price Target$50.60$25.00$19.75$30.29$27.80
% Upside from Price Target84.13% upside9.36% upside152.56% upside37.16% upside26.25% upside
Trade Information
Market Cap$751.39 million$818.85 million$510.17 million$595.21 million$842.61 million
Beta1.481.273.340.150.83
Average Volume760,334554,8281,368,585526,435171,330
Sales & Book Value
Annual Revenue$148.36 million$296.70 millionN/A$8 million$31.13 million
Price / Sales5.182.71N/A75.5326.97
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.73 per share$2.61 per share$1.72 per share$14.93 per share$5.61 per share
Price / Book37.648.76N/A1.483.93
Profitability
Net Income$-97,170,000.00$-22,720,000.00$-43,280,000.00$-97,340,000.00$-55,150,000.00
EPS($3.59)($0.68)($1.06)($3.60)($2.33)
Trailing P/E RatioN/A46.65N/AN/AN/A
Forward P/E RatioN/A13.85N/AN/AN/A
P/E GrowthN/A0.73N/AN/AN/A
Net Margins-46.15%5.71%N/AN/A-295.98%
Return on Equity (ROE)-629.88%12.64%-67.66%-19.09%-78.70%
Return on Assets (ROA)-41.43%3.15%-62.27%-17.94%-36.12%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A1.27%N/AN/AN/A
Current Ratio3.20%1.08%9.23%14.13%4.43%
Quick Ratio3.08%1.01%9.23%14.13%4.43%
Ownership Information
Institutional Ownership PercentageN/AN/A39.42%N/A62.57%
Insider Ownership Percentage7.70%8.08%14.40%13.00%7.40%
Miscellaneous
Employees479234599493
Shares Outstanding27.94 million35.20 million63.38 million27.37 million38.13 million
Next Earnings Date5/4/2021 (Confirmed)5/6/2021 (Confirmed)5/6/2021 (Estimated)5/5/2021 (Estimated)5/10/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableNot Optionable
SourceHeadline
Global Acenocoumarol Market 2021 Key Players – Novartis, Mylan, Teva, Merus Labs – Clark County Blog - Clark County BlogGlobal Acenocoumarol Market 2021 Key Players – Novartis, Mylan, Teva, Merus Labs – Clark County Blog - Clark County Blog
clarkcountyblog.com - April 20 at 12:39 AM
Dragon Ball Super Reveals a Subtle Secret About the Angels Powers - ComicBook.comDragon Ball Super Reveals a Subtle Secret About the Angels' Powers - ComicBook.com
comicbook.com - April 19 at 7:38 PM
Merus (NASDAQ:MRUS) Shares Gap Down to $22.52Merus (NASDAQ:MRUS) Shares Gap Down to $22.52
americanbankingnews.com - April 19 at 12:48 PM
Melanoma Vaccine Market 2021 Growth Analysis and Forecast Report 2021-2027 : Sanofi, GlaxoSmithKline, Merus, Medarex, Jounce Therapeutics, Bayer, Roche, Pfizer, Servier, Amgen - Clark County BlogMelanoma Vaccine Market 2021 Growth Analysis and Forecast Report 2021-2027 : Sanofi, GlaxoSmithKline, Merus, Medarex, Jounce Therapeutics, Bayer, Roche, Pfizer, Servier, Amgen - Clark County Blog
clarkcountyblog.com - April 19 at 9:35 AM
Dragon Ball Super: Is Vegeta Stronger Than Broly? | CBR - CBR - Comic Book ResourcesDragon Ball Super: Is Vegeta Stronger Than Broly? | CBR - CBR - Comic Book Resources
cbr.com - April 18 at 8:40 AM
Bispecific Antibody Market 2021 Competitive Dynamics & Outlook 2027 | Amgen, Merus, NovImmune SA, Jounce Therapeutics, Eli Lilly, Sanofi, Bayer, Pfizer, Roche, EMD Serono - Los Hijos de la MalincheBispecific Antibody Market 2021 Competitive Dynamics & Outlook 2027 | Amgen, Merus, NovImmune SA, Jounce Therapeutics, Eli Lilly, Sanofi, Bayer, Pfizer, Roche, EMD Serono - Los Hijos de la Malinche
loshijosdelamalinche.com - April 16 at 7:19 AM
Stake Chophouse & Bar is Giving Away A Dozen Oysters Every Week! - Coronado Times NewspaperStake Chophouse & Bar is Giving Away A Dozen Oysters Every Week! - Coronado Times Newspaper
coronadotimes.com - April 15 at 3:28 PM
Contrasting Merus (NASDAQ:MRUS) and ADVANZ PHARMA (OTCMKTS:CXRXF)Contrasting Merus (NASDAQ:MRUS) and ADVANZ PHARMA (OTCMKTS:CXRXF)
americanbankingnews.com - April 14 at 6:44 PM
Zenocutuzumab Shows Ability to Inhibit NRG1 Fusion–Positive Tumors - Cancer NetworkZenocutuzumab Shows Ability to Inhibit NRG1 Fusion–Positive Tumors - Cancer Network
cancernetwork.com - April 14 at 1:47 PM
William Blair Begins Coverage on Merus (NASDAQ:MRUS)William Blair Begins Coverage on Merus (NASDAQ:MRUS)
americanbankingnews.com - April 14 at 10:10 AM
Dragon Ball Super: Every Time Goku Turned Super Saiyan God (In Chronological Order) - CBRDragon Ball Super: Every Time Goku Turned Super Saiyan God (In Chronological Order) - CBR
cbr.com - April 14 at 3:45 AM
Receptor Tyrosine Protein Kinase ERBB 3 Market 2021 Industry Growth by Manufacturers, Regions, Share, Type Application and Forecast Analysis to 2029 14NER Oncology Inc., AstraZeneca, AVEO Pharmaceuticals – ROUGH Magazine - ROUGH MagazineReceptor Tyrosine Protein Kinase ERBB 3 Market 2021 Industry Growth by Manufacturers, Regions, Share, Type Application and Forecast Analysis to 2029 14NER Oncology Inc., AstraZeneca, AVEO Pharmaceuticals – ROUGH Magazine - ROUGH Magazine
rough.asia - April 12 at 8:07 PM
Merus (NASDAQ:MRUS) to Post Q1 2021 Earnings of ($0.69) Per Share, William Blair ForecastsMerus (NASDAQ:MRUS) to Post Q1 2021 Earnings of ($0.69) Per Share, William Blair Forecasts
americanbankingnews.com - April 12 at 1:14 AM
Zenocutuzumab Effectively Blocks Growth of NRG1 Fusion-Driven Tumors - Targeted OncologyZenocutuzumab Effectively Blocks Growth of NRG1 Fusion-Driven Tumors - Targeted Oncology
targetedonc.com - April 10 at 2:52 PM
Tyler ISD fourth graders combine entrepreneurial skills, big hearts to help classmates - Tyler Morning TelegraphTyler ISD fourth graders combine entrepreneurial skills, big hearts to help classmates - Tyler Morning Telegraph
tylerpaper.com - April 9 at 6:45 PM
Tyler ISD students create business to help fellow classmates - CBS19.tv KYTXTyler ISD students create business to help fellow classmates - CBS19.tv KYTX
cbs19.tv - April 8 at 10:58 PM
Why Is It Moving? Looking Into Why Meruss Stock is Trading Higher Today - BenzingaWhy Is It Moving? Looking Into Why Merus's Stock is Trading Higher Today - Benzinga
benzinga.com - April 8 at 12:34 PM
Merus (NASDAQ:MRUS) Given Consensus Recommendation of "Buy" by BrokeragesMerus (NASDAQ:MRUS) Given Consensus Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 8 at 8:50 AM
Merus (NASDAQ:MRUS) Earns Outperform Rating from Analysts at William BlairMerus (NASDAQ:MRUS) Earns Outperform Rating from Analysts at William Blair
americanbankingnews.com - April 8 at 7:58 AM
Merus (NASDAQ:MRUS) Shares Gap Up to $21.59Merus (NASDAQ:MRUS) Shares Gap Up to $21.59
americanbankingnews.com - April 5 at 12:46 PM
Zacks: Analysts Anticipate Merus (NASDAQ:MRUS) Will Announce Quarterly Sales of $26.13 MillionZacks: Analysts Anticipate Merus (NASDAQ:MRUS) Will Announce Quarterly Sales of $26.13 Million
americanbankingnews.com - April 5 at 3:14 AM
-$0.11 EPS Expected for Merus (NASDAQ:MRUS) This Quarter-$0.11 EPS Expected for Merus (NASDAQ:MRUS) This Quarter
americanbankingnews.com - April 3 at 10:14 AM
Cults and garagistes and the story of Mark Herold Wines - Napa Valley RegisterCults and garagistes and the story of Mark Herold Wines - Napa Valley Register
napavalleyregister.com - April 1 at 5:41 PM
What’s on deck today at TC Early Stage 2021 - TechCrunchWhat’s on deck today at TC Early Stage 2021 - TechCrunch
techcrunch.com - April 1 at 12:40 PM
Merus (NASDAQ:MRUS) Shares Gap Down to $19.50Merus (NASDAQ:MRUS) Shares Gap Down to $19.50
americanbankingnews.com - March 30 at 11:45 AM
Zacks Investment Research Upgrades Merus (NASDAQ:MRUS) to HoldZacks Investment Research Upgrades Merus (NASDAQ:MRUS) to Hold
marketbeat.com - March 20 at 2:10 AM
DateCompanyBrokerageAction
3/17/2021Esperion TherapeuticsMorgan StanleyInitiated Coverage
3/3/2021Esperion TherapeuticsNeedham & Company LLCLower Price Target
2/12/2021Esperion TherapeuticsJefferies Financial GroupDowngrade
2/9/2021Esperion TherapeuticsThe Goldman Sachs GroupDowngrade
1/15/2021Esperion TherapeuticsBank of AmericaDowngrade
11/10/2020Esperion TherapeuticsCredit Suisse GroupUpgrade
9/29/2020Esperion TherapeuticsJPMorgan Chase & Co.Initiated Coverage
8/10/2020Esperion TherapeuticsStifel NicolausReiterated Rating
6/23/2020Esperion TherapeuticsNorthland SecuritiesInitiated Coverage
5/7/2020Esperion TherapeuticsCitigroupBoost Price Target
1/11/2021Collegium PharmaceuticalHC WainwrightBoost Price Target
7/14/2020Collegium PharmaceuticalBWS FinancialInitiated Coverage
5/26/2020Collegium PharmaceuticalGuggenheimInitiated Coverage
2/28/2020Collegium PharmaceuticalWilliam BlairReiterated Rating
2/12/2020Collegium PharmaceuticalPiper SandlerBoost Price Target
2/7/2020Collegium PharmaceuticalCantor FitzgeraldBoost Price Target
4/19/2021Provention BioChardan CapitalLower Price Target
4/15/2021Provention BioSVB LeerinkLower Price Target
4/15/2021Provention BioRoyal Bank of CanadaReiterated Rating
4/9/2021Provention BioOppenheimerReiterated Rating
3/22/2021AnaptysBioTruist SecuritiesUpgrade
3/15/2021AnaptysBioWedbushReiterated Rating
3/3/2020AnaptysBioSunTrust BanksLower Price Target
1/19/2021MerusRoth CapitalBoost Price Target
3/27/2019MerusBerenberg BankInitiated Coverage
(Data available from 4/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.